
Replacing Insulin-Producing Cells: How Islet Transplantation and Stem Cell Research May Transform Type 1 Diabetes Treatment
Researchers are developing new ways to restore insulin production by transplanting lab-grown islet cells and reducing the immunosuppression burden. While still in development, these approaches represent a significant shift in how scientists think about managing Type 1 diabetes.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- Islet cell transplantation—replacing the insulin-producing cells damaged by Type 1 diabetes—has been used in Canada for 25 years, but remains available only to a small number of people at highest risk for complications.
- Researchers are now growing islet cells from stem cells in the laboratory rather than relying solely on deceased donor pancreases, potentially expanding access.
- A major focus is reducing the amount of immunosuppressive medication needed to prevent the transplanted cells from being attacked by the immune system.
- Canadian scientists, including teams at the University of British Columbia, are leading efforts to create stronger replacement cells and develop safer protection methods.
Understanding Islet Cells and Their Role in Type 1 Diabetes
Islet cells are clusters of cells within the pancreas that produce insulin—the hormone that unlocks glucose and allows it to be used as energy by the body. When you eat carbohydrates or sugar, your body converts them into glucose. Without insulin to open the door, that glucose cannot enter cells and cannot be used for energy.
In Type 1 diabetes, the immune system mistakenly attacks and destroys these islet cells. Once damaged, they can no longer produce insulin or the other hormones needed to regulate blood glucose. This is why people with Type 1 diabetes require insulin therapy to survive.
Islet Transplantation: A Functional Approach to Restoration
One approach to managing Type 1 diabetes is islet transplantation—replacing the damaged islet cells with healthy ones. This concept has been used in Canada for approximately 25 years. However, access has been very limited, reserved primarily for individuals facing the greatest risk of serious Type 1 diabetes complications.
Traditionally, transplanted islets have come from deceased donor pancreases. This approach requires the recipient to take immunosuppressive medications to prevent their immune system from attacking the new cells—a burden that limits how widely the procedure can be offered.
A New Direction: Lab-Grown Cells and Reduced Immunosuppression
Over the past two decades, researchers have reimagined islet transplantation in two major ways. First, instead of depending on deceased donor pancreases, scientists are now learning to grow islet cells from stem cells in the laboratory. This could potentially make transplantable cells more readily available.
Second, researchers are working to reduce the amount of immunosuppressive medication needed to protect transplanted islets from immune attack. Lowering this burden could make the procedure safer and more practical for more people.
These developments remain under investigation, but together they point toward a shared goal: restoring the body's natural insulin production while keeping the new cells safe from immune damage.
Canada's Leadership in Islet Research
Canada has a strong track record in islet transplantation research and continues to address some of the field's most pressing challenges. At the University of British Columbia, researchers funded by the Breakthrough T1D Canucks for Kids Fund Centre of Excellence are actively working to create stronger replacement cells and develop better ways to protect them from the immune system.
This ongoing work reflects the commitment of Canadian scientists to advance cell-based therapies that could one day offer new possibilities for people living with Type 1 diabetes.
Evidence label
Origin: breakthrought1d.ca (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
From Type1Cure
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Research summaryCure & AdvancementsCell Replacement Therapy: A New Frontier in Type 1 Diabetes ResearchVideo report, corroborated with 5 indexed studies
- Research summaryCure & AdvancementsWhy Beta Cells Die in Type 1 Diabetes While Alpha Cells SurviveNews report, corroborated with 2 indexed studies
- Research summaryCure & AdvancementsEarly Trial Shows Some People with Type 1 Diabetes Can Reduce or Stop Insulin—Here's What We KnowNews report, corroborated with 3 indexed studies
- Research summaryCure & AdvancementsBeta Cell Therapy: Moving From Lab Promise to Real-World TreatmentVideo report, corroborated with 2 indexed studies
- Research summaryCure & AdvancementsUnderstanding the Eleodon Trial: What Early Results ShowVideo report — unverified, pending corroboration
- Research summaryCure & AdvancementsIslet Cell Therapies Advance: What You Need to KnowNews report, corroborated with 3 indexed studies